Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, ...

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Will the FTC Be More PBM-Friendly Under a Second Trump Administration?